A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2015 by Celgene Corporation
Acceleron Pharma, Inc.
Information provided by (Responsible Party):
First received: June 16, 2010
Last updated: December 22, 2015
Last verified: December 2015
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is currently recruiting participants.|
|Estimated Study Completion Date:||January 2016|
|Estimated Primary Completion Date:||January 2016 (Final data collection date for primary outcome measure)|